Gains in life expectancy have been accompanied by a rise in age-related diseases, including Alzheimer’s disease, macular degeneration, and glaucoma. Geroscience, as a field, wants to reduce age-related diseases, and BrightFocus is excited about partnering with this interdisciplinary field. .
Geroscience, as a field, seeks to intervene with aspects of aging that increase the risk of disease. In a Q&A, BrightFocus VP of Scientific Affairs Diane Bovenkamp, PhD, thinks that could help find cures for diseases of mind and sight.
The BrightFocus Glaucoma Fast Track Workshop is a day-long workshop providing a unique immersive environment for early-stage scientists focused on glaucoma research or those who want to enter the field to accelerate their path towards becoming an expert in this exciting field.
This publication provides information on what glaucoma is, the various forms of glaucoma, tips for lowering risk, how this eye disease is diagnosed and treated, and essential questions to ask your doctor after a diagnosis.
Learn about the two forms of age-related macular degeneration (AMD), the importance of early diagnosis, healthy habits that may reduce the risk of developing AMD, and how to monitor your sight if you have this eye disease.
The discussion features Edward Marcus, MD, from SightMD in Brentwood, New York. Dr. Marcus specializes in medical and surgical management of retinal diseases, including diabetic retinopathy, macular degeneration, and retinal detachment. He also specializes in treating inflammatory and infectious eye diseases.
The telephone discussion features Emily Y. Chew, MD, who is a retina specialist and is the deputy director of the Division of Epidemiology and Clinical Applications, and the deputy clinical director at the National Eye Institute (NEI), National Institutes of Health (NIH). Dr. Chew has extensive experience in age-related eye diseases, and designing and implementing clinical trials, including the Age-Related Eye Disease Study 2 (AREDS2). View the transcript Print the transcript Listen to the discussion:
A BrightFocus Foundation-funded project to develop a blood-based screening test for Alzheimer’s disease has passed proof of concept stage and C2N Diagnostics, the company spearheading the development of the test, will move forward to approve use in research and clinical settings, according to a presentation at a major scientific conference.
BrightFocus Foundation today announced that it has received a SHORTY Social Good Award® for the public impact of its nationwide screening tour of Turning Point, a documentary by acclaimed filmmaker James Keach.
BrightFocus is highly encouraged by Biogen’s announcement today that clinical trials of its experimental drug aducanumab reduced cognitive decline in some Alzheimer’s patients through improved cognition, memory, and activities of daily living.